[
  {
    "id": 1,
    "repeat_id": 1,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe prognostic factors analyzed in relation to disease-free survival and overall survival in node-positive patients included:  \n1. **Number of positive nodes** (univariate p < 0.0001, multivariate p < 0.0002).  \n2. **HER-2/NEU amplification** (univariate p < 0.0001, multivariate p < 0.0001).  \n3. **Tumor size** (univariate p = 0.05, multivariate p = 0.001).  \n4. **Log (PGR)** (univariate p = 0.05, multivariate p = 0.05).  \n5. **Age** (univariate p = 0.22, multivariate p = 0.61).  \nThe analysis highlighted **HER-2/NEU amplification** and **number of positive nodes** as statistically significant predictors of survival outcomes.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:53:38",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 13.02719497680664
  },
  {
    "id": 1,
    "repeat_id": 2,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe prognostic factors analyzed in relation to disease-free survival and overall survival in node-positive patients included:  \n1. **Number of positive nodes** (univariate p < 0.0001, multivariate p < 0.0002).  \n2. **HER-2/NEU amplification** (univariate p < 0.0001, multivariate p < 0.0001).  \n3. **Tumor size** (univariate p = 0.05, multivariate p = 0.001).  \n4. **Log (PGR)** (univariate p = 0.05, multivariate p = 0.05).  \n5. **Age** (univariate p = 0.22, multivariate p = 0.61).  \n**Key findings**:  \n- **HER-2/NEU amplification** and **number of positive nodes** were statistically significant predictors of survival outcomes.  \n- **Tumor size** and **log (PGR)** showed marginal significance in the multivariate analysis.  \n- **Age** did not reach statistical significance (p = 0.61).  \nThese factors were evaluated using a **Cox proportional hazards model** to assess their independent impact on survival.",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:53:43",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.638100862503052
  },
  {
    "id": 1,
    "repeat_id": 3,
    "question": "What prognostic factors were analyzed in relation to disease-free survival and overall survival in node-positive patients?",
    "answer": "\nThe prognostic factors analyzed in relation to disease-free survival and overall survival in node-positive patients included:  \n1. **Number of positive nodes** (univariate p < 0.0001, multivariate p < 0.0002).  \n2. **HER-2/NEU amplification** (univariate p < 0.0001, multivariate p < 0.0001).  \n3. **Tumor size** (univariate p = 0.05, multivariate p = 0.001).  \n4. **Log (PGR)** (univariate p = 0.05, multivariate p = 0.05).  \n5. **Age** (univariate p = 0.22, multivariate p = 0.61).  \n**Key findings**:  \n- **HER-2/NEU amplification** and **number of positive nodes** were statistically significant predictors of survival outcomes.  \n- **Tumor size** and **log (PGR)** showed marginal significance in the multivariate analysis.  \n- **Age** did not reach statistical significance (p = 0.61).",
    "ground_truth": "The excerpt indicates that the prognostic factors analyzed include the number of positive nodes and HER-2/neu status. Specifically, the paper states: 'number of positive nodes 0. 0001 0. 0002' and 'her - 2 / neu 0. 0011 < 0. 0001'. This demonstrates that both factors are statistically significant in predicting survival outcomes.",
    "source": "'number of positive nodes 0. 0001 0. 0002 her - 2 / neu 0. 0011 < 0. 0001'",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:53:47",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.851320505142212
  },
  {
    "id": 2,
    "repeat_id": 1,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of a ligand in breast cancer can have significant therapeutic implications, depending on the ligand's role in tumor biology. Here are key potential implications:\n### 1. **Targeting Receptor Signaling Pathways**  \n   - If the ligand binds to **receptors** (e.g., HER2, EGFR, or other tyrosine kinase receptors), targeting it could inhibit tumor growth by blocking aberrant signaling.  \n   - **Examples**: Monoclonal antibodies (e.g., trastuzumab for HER2 overexpression) or small molecules that inhibit receptor activity.  \n### 2. **Inhibition of Cytokine or Growth Factor Signaling**  \n   - If the ligand is a **cytokine** (e.g., TNF-\u03b1, IL-6) or **growth factor** (e.g., PDGF, VEGF), blocking its activity could suppress angiogenesis, immune evasion, or tumor proliferation.  \n   - **Examples**: Anti-VEGF therapies (e.g., bevacizumab) or anti-TNF-\u03b1 agents.  \n### 3. **Enhanced Immunotherapy**  \n   - Ligands involved in **immune checkpoint regulation** (e.g., PD-1, PD-L1) could be targets for immunotherapy, such as checkpoint inhibitors (e.g., pembrolizumab), to boost the immune system's ability to attack cancer cells.  \n### 4. **Combination Therapies**  \n   - Identifying the ligand may enable **combination strategies** (e.g., targeting ligand + receptor + downstream pathways) to overcome resistance.  \n   - **Examples**: Dual inhibitors (e.g., combining HER2-targeted therapies with anti-VEGF agents).  \n### 5. **Personalized Medicine**  \n   - The ligand\u2019s role in individual tumors can guide **precision therapies**, such as **CDx (Cancer Drug Discovery)** approaches, tailoring treatments to specific molecular profiles.  \n### 6. **Prevention of Metastasis**  \n   - If the ligand is involved in **metastatic progression** (e.g., promoting cell migration or survival), targeting it could reduce tumor spread.  \n### 7. **Drug Development**  \n   - The ligand may serve as a **lead compound** for developing novel drugs (e.g., small molecules, antibodies, or RNA interference) to disrupt its function.  \n### Key Considerations:  \n- **Mechanism of Action**: Whether the ligand is a receptor, cytokine, or enzyme determines the therapeutic approach.  \n- **Resistance**: Identifying the ligand may help address **resistance mechanisms** by targeting \"undruggable\" targets.  \n- **Clinical Trials**: Early-phase trials could validate the ligand\u2019s role and optimize therapeutic strategies.  \nIn summary, ligand identification opens avenues for **targeted therapies, immunotherapy, and combination strategies**, ultimately improving outcomes for patients with breast cancer.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:53:54",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 7.489877700805664
  },
  {
    "id": 2,
    "repeat_id": 2,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of a ligand in breast cancer can have transformative therapeutic implications, depending on its molecular role. Key implications include:\n### 1. **Targeted Receptor Inhibition**  \n   - If the ligand binds to **receptors** (e.g., HER2, EGFR), therapies targeting the ligand or its receptor can disrupt aberrant signaling.  \n   - **Examples**: Monoclonal antibodies (e.g., trastuzumab) or small molecules that inhibit receptor activity.  \n### 2. **Cytokine or Growth Factor Blockade**  \n   - Ligands involved in **immune evasion** (e.g., PD-1, PD-L1) or **angiogenesis** (e.g., VEGF) can be targeted to suppress tumor growth.  \n   - **Examples**: Anti-VEGF drugs (e.g., bevacizumab) or anti-TNF-\u03b1 agents.  \n### 3. **Immunotherapy Enhancement**  \n   - Ligands that regulate **immune checkpoints** (e.g., PD-1, PD-L1) can enable **checkpoint inhibitors** (e.g., pembrolizumab) to boost immune cell activity against tumors.  \n### 4. **Combination Therapies**  \n   - Ligand identification may allow **synergistic combinations** (e.g., ligand + receptor inhibitor + anti-angiogenic agent) to overcome resistance.  \n### 5. **Personalized Medicine**  \n   - The ligand\u2019s role in individual tumors can guide **precision therapies**, such as **CDx (Cancer Drug Discovery)** approaches, tailoring treatments to specific molecular profiles.  \n### 6. **Prevention of Metastasis**  \n   - If the ligand promotes **metastatic progression** (e.g., cell migration or survival), targeting it could reduce tumor spread.  \n### 7. **Drug Development**  \n   - The ligand may serve as a **lead compound** for novel therapies (e.g., small molecules, antibodies, or RNA interference) to disrupt its function.  \n### Key Considerations:  \n- **Mechanism of Action**: The ligand\u2019s role (receptor, cytokine, enzyme) determines the therapeutic strategy.  \n- **Resistance**: Identifying the ligand may help address **resistance mechanisms** by targeting \"undruggable\" targets.  \n- **Clinical Trials**: Early-phase trials can validate the ligand\u2019s role and optimize therapeutic strategies.  \nIn summary, ligand identification opens pathways for **targeted therapies, immunotherapy, and combination strategies**, ultimately improving outcomes for patients with breast cancer.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:00",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.763237714767456
  },
  {
    "id": 2,
    "repeat_id": 3,
    "question": "What potential therapeutic implications are suggested by the identification of the ligand in breast cancer?",
    "answer": "\nThe identification of a ligand in breast cancer can drive transformative therapeutic strategies, with implications spanning **targeted therapies, immunotherapy, and personalized medicine**. Key implications include:\n### 1. **Receptor Targeting**  \n   - Inhibition of ligand-receptor interactions (e.g., HER2, EGFR) disrupts aberrant signaling, reducing tumor growth and metastasis.  \n   - **Examples**: Monoclonal antibodies (e.g., trastuzumab) or small-molecule inhibitors.\n### 2. **Cytokine/angiogenic Blockade**  \n   - Targeting ligands involved in immune evasion (e.g., PD-1, PD-L1) or angiogenesis (e.g., VEGF) suppresses tumor progression.  \n   - **Examples**: Anti-VEGF drugs (e.g., bevacizumab) or anti-TNF-\u03b1 agents.\n### 3. **Immunotherapy Enhancement**  \n   - Ligands regulating immune checkpoints (e.g., PD-1, PD-L1) enable **checkpoint inhibitors** (e.g., pembrolizumab) to boost immune cell activity against tumors.\n### 4. **Combination Therapies**  \n   - Ligand identification allows **synergistic combinations** (e.g., ligand + receptor inhibitor + anti-angiogenic agent) to overcome resistance and enhance efficacy.\n### 5. **Personalized Medicine**  \n   - The ligand\u2019s role in individual tumors guides **precision therapies**, such as **CDx (Cancer Drug Discovery)**, tailoring treatments to specific molecular profiles.\n### 6. **Metastasis Prevention**  \n   - Targeting ligands involved in metastatic progression (e.g., cell migration or survival) reduces tumor spread and improves prognosis.\n### 7. **Drug Development**  \n   - The ligand may serve as a **lead compound** for novel therapies (e.g., small molecules, antibodies, or RNA interference) to disrupt its function.\n### Key Considerations:  \n- **Mechanism of Action**: The ligand\u2019s role (receptor, cytokine, enzyme) determines the therapeutic strategy.  \n- **Resistance**: Identifying the ligand helps address **resistance mechanisms** by targeting \"undruggable\" targets.  \n- **Clinical Trials**: Early-phase trials validate the ligand\u2019s role and optimize therapeutic strategies.\nIn summary, ligand identification opens pathways for **targeted therapies, immunotherapy, and combination strategies**, ultimately improving outcomes for patients with breast cancer.",
    "ground_truth": "The identification of its ligand and the development of specific antagonists could have important therapeutic implications. Specifically, the paper states: 'identification of its ligand and development of specific antagonists could have important therapeutic implications.' This demonstrates that targeting the ligand may lead to new treatment strategies for breast cancer.",
    "source": "identification of its ligand and development of specific antagonists could have important therapeutic implications.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:06",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.709744691848755
  },
  {
    "id": 3,
    "repeat_id": 1,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe HER2 (Human Epidermal Growth Factor Receptor 2) oncogene plays a critical role in the progression and prognosis of human breast cancer. Its significance is multifaceted and has been a cornerstone in both **targeted therapy** and **clinical outcomes**. Here\u2019s a structured overview of its importance:\n### 1. **Overexpression and Prognosis**  \n   - HER2 is overexpressed in approximately **15-20% of breast cancers**, particularly in **luminal A** and **luminal B** subtypes.  \n   - Patients with HER2-positive tumors often have **poorer survival rates** compared to HER2-negative tumors, necessitating specific therapeutic interventions.\n### 2. **Targeted Therapies**  \n   - **HER2-targeted therapies** (e.g., trastuzumab, pertuzumab) have revolutionized treatment by directly inhibiting HER2 activity.  \n   - These therapies work by **blocking HER2-mediated signaling** (e.g., EGFR, PDGFR) and **impeding tumor growth** and metastasis.  \n   - **Combination therapies** (e.g., HER2 + chemotherapy) have improved survival rates and reduced tumor size.\n### 3. **Immunotherapy**  \n   - HER2-positive tumors can be **targeted for immunotherapy** (e.g., checkpoint inhibitors like pembrolizumab) to enhance immune cell activity against cancer cells.  \n   - **CDx (Cancer Drug Discovery)** approaches leverage HER2\u2019s role in tumor biology to develop novel therapies.\n### 4. **Clinical Outcomes**  \n   - **HER2-positive patients** benefit from **significantly improved survival** and **response rates** with targeted therapies.  \n   - **HER2-negative patients** often face **higher mortality** and require **more aggressive treatment strategies** (e.g., chemotherapy).\n### 5. **Pathogenesis**  \n   - HER2 is a **proto-oncogene** that, when overexpressed, drives **cell proliferation, survival, and metastasis**.  \n   - Its activation is often linked to **genomic instability** and **tumor heterogeneity**, contributing to resistance to therapy.\n### 6. **Research and Biomarker**  \n   - HER2 is a **key biomarker** for **precision medicine**, guiding treatment decisions.  \n   - Its overexpression is associated with **specific genetic mutations** (e.g., amplification of the *TP53* gene) and **tumor subtypes**.\n### 7. **Challenges and Future Directions**  \n   - **Resistance** to HER2-targeted therapies remains a challenge, necessitating **combination therapies** and **novel agents** (e.g., PARP inhibitors).  \n   - **Liquid biopsies** and **single-cell sequencing** are being explored to monitor HER2 status and resistance in real-time.\n### Conclusion  \nThe HER2 oncogene is a **critical driver of breast cancer progression** and a **target for precision therapies**. Its significance lies in its role in **prognosis, treatment efficacy, and biomarker status**, making it a focal point in both **clinical practice** and **research**. Advances in HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, underscoring its importance in modern oncology.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:11",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.395824432373047
  },
  {
    "id": 3,
    "repeat_id": 2,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe HER2 (Human Epidermal Growth Factor Receptor 2) oncogene is a pivotal driver of breast cancer progression and a key target for therapeutic intervention. Its significance lies in several critical areas:\n### 1. **Clinical Relevance**  \n   - **Overexpression/Amplification**: HER2 is overexpressed in ~15-20% of breast cancers, particularly in **luminal A** and **B** subtypes.  \n   - **Prognostic Impact**: HER2-positive patients often have **poorer survival rates** compared to HER2-negative tumors, necessitating tailored therapies.\n### 2. **Therapeutic Targets**  \n   - **Targeted Therapies**: Drugs like **trastuzumab** (pertuzumab) inhibit HER2 activity, blocking tumor growth and metastasis.  \n   - **Combination Therapies**: HER2-targeted therapies often pair with **chemotherapy** (e.g., paclitaxel) or **PD-1/PD-L1 inhibitors** to enhance efficacy.\n### 3. **Immunotherapy**  \n   - HER2-positive tumors can be **targeted for immunotherapy** (e.g., **pembrolizumab**) to activate immune cells against cancer cells.\n### 4. **Biomarker and Precision Medicine**  \n   - HER2 is a **critical biomarker** for **precision medicine**, guiding treatment decisions and predicting response to therapy.  \n   - Its overexpression is often linked to **genomic instability** and **tumor heterogeneity**, influencing therapeutic strategies.\n### 5. **Challenges and Future Directions**  \n   - **Resistance**: HER2-targeted therapies can fail due to **resistance** or **tumor heterogeneity**, requiring **combination approaches** (e.g., PARP inhibitors).  \n   - **Liquid Biopsies**: Advances in **liquid biopsies** allow real-time monitoring of HER2 status and resistance.\n### Conclusion  \nHER2 is a **cornerstone of breast cancer treatment**, with significant implications for **prognosis, therapy selection, and patient outcomes**. Its role in **precision medicine** and **targeted therapies** has transformed clinical practice, offering improved survival rates for HER2-positive patients.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:17",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.777787923812866
  },
  {
    "id": 3,
    "repeat_id": 3,
    "question": "What is the significance of the her-2/neu oncogene in human breast cancer as discussed in the excerpt?",
    "answer": "\nThe HER2 (Human Epidermal Growth Factor Receptor 2) oncogene is a critical driver of breast cancer progression and a key target for therapeutic intervention. Its significance lies in several key areas:\n### 1. **Biomarker and Prognosis**  \n   - HER2 overexpression is associated with **poorer survival rates** in breast cancer, making it a **critical biomarker** for **precision medicine**.  \n   - Patients with HER2-positive tumors benefit from **targeted therapies** that directly inhibit HER2 activity.\n### 2. **Therapeutic Impact**  \n   - **Targeted Therapies**: Drugs like **trastuzumab** (pertuzumab) and **lapatinib** inhibit HER2, reducing tumor size and metastasis.  \n   - **Combination Therapies**: HER2-targeted therapies often pair with **chemotherapy** (e.g., paclitaxel) or **PD-1/PD-L1 inhibitors** to enhance efficacy.\n### 3. **Immunotherapy**  \n   - HER2-positive tumors can be **targeted for immunotherapy** (e.g., **pembrolizumab**) to activate immune cells against cancer cells.\n### 4. **Clinical Implications**  \n   - HER2 status guides **treatment selection** and predicts response to therapy.  \n   - Its overexpression is often linked to **genomic instability** and **tumor heterogeneity**, influencing therapeutic strategies.\n### 5. **Future Directions**  \n   - Advances in **liquid biopsies** allow real-time monitoring of HER2 status and resistance.  \n   - Combination therapies (e.g., HER2 + chemotherapy) improve outcomes for HER2-positive patients.\n### Conclusion  \nHER2 is a **cornerstone of breast cancer treatment**, with significant implications for **prognosis, therapy selection, and patient outcomes**. Its role in **precision medicine** and **targeted therapies** has transformed clinical practice, offering improved survival rates for HER2-positive patients.",
    "ground_truth": "The her-2/neu oncogene is significant in human breast cancer as it has been shown to be amplified in breast cancer cell lines. Specifically, the paper states: 'this gene has been shown to be amplified in human breast cancer cell lines.' This demonstrates that amplification of this oncogene may correlate with disease progression.",
    "source": "'this gene has been shown to be amplified in human breast cancer cell lines.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:22",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.834783315658569
  },
  {
    "id": 4,
    "repeat_id": 1,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe analysis of HER2/neu gene alterations in the study likely employed **next-generation sequencing (NGS)** or **immunohistochemistry (IHC)** to identify genetic mutations, expression levels, or protein overexpression. These methods are commonly used in cancer research to detect biomarkers and guide therapeutic strategies. For example:  \n- **NGS** could identify mutations or copy-number variations in the HER2 gene.  \n- **IHC** would measure HER2 protein expression levels in tissue samples.  \nThe exact method would depend on the study's objectives (e.g., biomarker validation, therapeutic target identification) and available resources. If the study focused on specific mechanisms, additional details (e.g., RNA sequencing, expression profiling) might have been used.",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:26",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.9071550369262695
  },
  {
    "id": 4,
    "repeat_id": 2,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe analysis of HER2/neu gene alterations in the study likely utilized **next-generation sequencing (NGS)** to identify genetic mutations or copy-number variations, or **immunohistochemistry (IHC)** to measure HER2 protein expression levels. These methods are standard in cancer research to detect biomarkers and guide therapeutic strategies. The exact technique would depend on the study's specific goals (e.g., biomarker validation, therapeutic target identification).",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:28",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.648972511291504
  },
  {
    "id": 4,
    "repeat_id": 3,
    "question": "What method was used to analyze alterations in the her - 2 / neu gene in the study?",
    "answer": "\nThe analysis of HER2/neu gene alterations in the study likely employed **next-generation sequencing (NGS)** to identify genetic mutations or copy-number variations, or **immunohistochemistry (IHC)** to measure HER2 protein expression levels. These methods are standard in cancer research to detect biomarkers and guide therapeutic strategies. The exact technique would depend on the study's specific goals (e.g., biomarker validation, therapeutic target identification).",
    "ground_truth": "The study utilized Southern blot analysis to evaluate alterations in the her - 2 / neu gene. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.' This demonstrates that the researchers employed a molecular technique to detect specific genetic alterations.",
    "source": "'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32 p - labeled her - 2 / neu - 1 probe.'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:31",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.3869869709014893
  },
  {
    "id": 5,
    "repeat_id": 1,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate HER2/neu gene alterations in breast cancer tumors would depend on the study's design. Common methods include:  \n- **Immunohistochemistry (IHC)**: Uses HER2-specific monoclonal antibodies (e.g., 184-32A4) to detect protein overexpression.  \n- **Fluorescent in situ hybridization (FISH)**: Combines fluorescent probes with DNA arrays to quantify HER2 copy-number variations.  \n- **Next-generation sequencing (NGS)**: Identifies mutations or copy-number changes using targeted sequencing or whole-exome sequencing.  \nThe exact probe and technique would align with the study's goals (e.g., biomarker validation, therapeutic target identification). For example, IHC with HER2-specific antibodies is widely used for clinical diagnostics, while FISH is common in research to assess HER2 amplification. The specific method is determined by the study's objectives and available resources.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:34",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.3630118370056152
  },
  {
    "id": 5,
    "repeat_id": 2,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate HER2/neu gene alterations in breast cancer tumors typically depend on the study's design and goals. Common methods include:  \n- **Immunohistochemistry (IHC)**: Uses HER2-specific monoclonal antibodies (e.g., 184-32A4) to detect protein overexpression.  \n- **Fluorescent In Situ Hybridization (FISH)**: Combines fluorescent probes with DNA arrays to quantify HER2 copy-number variations.  \n- **Next-Generation Sequencing (NGS)**: Identifies mutations or copy-number changes using targeted sequencing or whole-exome sequencing.  \nThe exact probe and technique would align with the study's objectives (e.g., biomarker validation, therapeutic target identification). For example, IHC with HER2-specific antibodies is widely used in clinical diagnostics, while FISH is common in research to assess HER2 amplification. The specific method is determined by the study's design and available resources.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:38",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.760216474533081
  },
  {
    "id": 5,
    "repeat_id": 3,
    "question": "What specific technique and probe were used to evaluate alterations in the HER-2/neu gene in breast cancer tumors?",
    "answer": "\nThe specific technique and probe used to evaluate HER2/neu gene alterations in breast cancer tumors are typically determined by the study's design and goals. Common methods include:  \n- **Immunohistochemistry (IHC)**: Uses HER2-specific monoclonal antibodies (e.g., 184-32A4) to detect protein overexpression.  \n- **Fluorescent In Situ Hybridization (FISH)**: Combines fluorescent probes with DNA arrays to quantify HER2 copy-number variations.  \n- **Next-Generation Sequencing (NGS)**: Identifies mutations or copy-number changes using targeted sequencing or whole-exome sequencing.  \nThe exact probe and technique would align with the study's objectives (e.g., biomarker validation, therapeutic target identification). For example, IHC with HER2-specific antibodies is widely used in clinical diagnostics, while FISH is common in research to assess HER2 amplification. The specific method is determined by the study's design and available resources.",
    "ground_truth": "According to the excerpt, Southern blot analysis with a 32P-labeled HER-2/neu-1 probe was used to evaluate alterations in the HER-2/neu gene in breast cancer tumors. Specifically, the paper states: 'dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.' This demonstrates that the researchers used a specific molecular biology technique (Southern blot) with a radioactively labeled probe to detect gene amplification in tumor DNA samples.",
    "source": "dna from individual tumors was prepared as described, digested with eco ri, and subjected to southern blot analysis with a 32p - labeled her - 2 / neu - 1 probe, which is known to detect a 13 - kb hybridizing band in human dna.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:41",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.6762681007385254
  },
  {
    "id": 6,
    "repeat_id": 1,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe specific observations regarding the HER2/neu loci in the study depend on the experimental design and methodology employed. Common findings include:  \n- **Protein Overexpression**: In IHC-based studies, HER2/neu is often overexpressed in breast cancer tissues, particularly in aggressive subtypes like HER2-positive tumors.  \n- **Copy-Number Variations (CNVs)**: FISH analyses frequently show amplification of the HER2 gene, indicating genomic instability.  \n- **Mutation Analysis**: NGS studies may reveal specific mutations or deletions in the HER2 gene, though these are rare in breast cancer.  \nThe exact observations would be context-dependent on the study's objectives (e.g., biomarker validation, therapeutic targets). For example, HER2-positive tumors are typically characterized by elevated HER2 protein levels or amplified genomic regions. The specific results are not provided here, as they vary by study design.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:54:45",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.443042755126953
  },
  {
    "id": 6,
    "repeat_id": 2,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe specific observations regarding the HER2/neu loci in the study depend on the experimental design and methodology. Common findings include:  \n- **Protein Overexpression**: In IHC-based studies, HER2/neu is often overexpressed in breast cancer tissues, particularly in HER2-positive subtypes.  \n- **Copy-Number Variations (CNVs)**: FISH analyses frequently show amplification of the HER2 gene, indicating genomic instability.  \n- **Mutation Analysis**: NGS studies may reveal specific mutations or deletions in the HER2 gene, though these are rare in breast cancer.  \nThe exact observations would vary based on the study's goals (e.g., biomarker validation, therapeutic targets). For example, HER2-positive tumors are typically characterized by elevated HER2 protein levels or amplified genomic regions. The specific results are not provided here, as they depend on the study's design.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:54:48",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8623499870300293
  },
  {
    "id": 6,
    "repeat_id": 3,
    "question": "What was observed regarding the HER-2/neu loci in the study?",
    "answer": "\nThe specific observations regarding the HER2/neu loci in the study depend on the experimental design and methodology. Common findings include:  \n- **Protein Overexpression**: In IHC-based studies, HER2/neu is often overexpressed in breast cancer tissues, particularly in HER2-positive subtypes.  \n- **Copy-Number Variations (CNVs)**: FISH analyses frequently show amplification of the HER2 gene, indicating genomic instability.  \n- **Mutation Analysis**: NGS studies may reveal specific mutations or deletions in the HER2 gene, though these are rare in breast cancer.  \nThe exact observations would vary based on the study's goals (e.g., biomarker validation, therapeutic targets). For example, HER2-positive tumors are typically characterized by elevated HER2 protein levels or amplified genomic regions. The specific results are not provided here, as they depend on the study's design.",
    "ground_truth": "The study observed that in two of the three cases, the rearrangement of the HER-2/neu loci was identical, and additionally, two of the rearranged HER-2/neu loci were amplified. Specifically, the excerpt states: 'also, two of the rearranged her - 2 / neu loci were amplified.' This indicates a potential significance of these rearrangements in the context of breast cancer.",
    "source": "'also, two of the rearranged her - 2 / neu loci were amplified.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:54:51",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8825361728668213
  },
  {
    "id": 7,
    "repeat_id": 1,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the HER2/neu and EGFR genes differ in size due to their distinct structural features:\n1. **HER2/neu (ErbB-2)**:  \n   - The HER2/neu protein is a transmembrane receptor tyrosine kinase (RTK) that spans the cell membrane.  \n   - It consists of an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **190 kDa** (190,000 Da).  \n2. **EGFR (ErbB-1/ErbB-4)**:  \n   - EGFR is also an RTK, but its structure differs slightly.  \n   - It has an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **210 kDa** (210,000 Da).  \n**Key Differences**:  \n- **Size**: HER2/neu (190 kDa) is slightly smaller than EGFR (210 kDa).  \n- **Post-translational Modifications**: HER2/neu may undergo additional modifications (e.g., glycosylation) that increase its molecular weight, while EGFR is less commonly modified.  \nThese differences in size and structure contribute to their distinct biological functions and roles in cancer progression.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:53",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.771976947784424
  },
  {
    "id": 7,
    "repeat_id": 2,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the HER-2/neu and EGFR genes differ in size due to their distinct structural features:\n1. **HER-2/neu (ErbB-2)**:  \n   - The HER-2/neu protein is a transmembrane receptor tyrosine kinase (RTK) that spans the cell membrane.  \n   - It consists of an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **190 kDa** (190,000 Da).  \n2. **EGFR (ErbB-1/ErbB-4)**:  \n   - EGFR is also an RTK, but its structure differs slightly.  \n   - It has an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **210 kDa** (210,000 Da).  \n**Key Differences**:  \n- **Size**: HER-2/neu (190 kDa) is slightly smaller than EGFR (210 kDa).  \n- **Post-translational Modifications**: HER-2/neu may undergo additional modifications (e.g., glycosylation) that increase its molecular weight, while EGFR is less commonly modified.  \nThese differences in size and structure contribute to their distinct biological functions and roles in cancer progression.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:56",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.7916316986083984
  },
  {
    "id": 7,
    "repeat_id": 3,
    "question": "How do the proteins produced by the HER-2/neu and EGFR genes differ in size?",
    "answer": "\nThe proteins produced by the HER-2/neu and EGFR genes differ in size due to their distinct structural features:\n1. **HER-2/neu (ErbB-2)**:  \n   - The HER-2/neu protein is a transmembrane receptor tyrosine kinase (RTK) that spans the cell membrane.  \n   - It consists of an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **190 kDa** (190,000 Da).  \n2. **EGFR (ErbB-1/ErbB-4)**:  \n   - EGFR is also an RTK, but its structure differs slightly.  \n   - It has an extracellular domain (ligand-binding region), a transmembrane domain, and a cytoplasmic tyrosine kinase domain.  \n   - The full-length protein is approximately **210 kDa** (210,000 Da).  \n**Key Differences**:  \n- **Size**: HER-2/neu (190 kDa) is slightly smaller than EGFR (210 kDa).  \n- **Post-translational Modifications**: HER-2/neu may undergo additional modifications (e.g., glycosylation) that increase its molecular weight, while EGFR is less commonly modified.  \nThese differences in size and structure contribute to their distinct biological functions and roles in cancer progression.",
    "ground_truth": "According to the excerpt, the protein encoded by the HER-2/neu gene is larger than the protein encoded by the EGFR gene. Specifically, the paper states that the HER-2/neu protein is \"185,000 daltons, as compared to the 170,000-dalton protein encoded by the egfr gene.\"",
    "source": "finally, the protein encoded by the her - 2 / neu gene is 185, 000 daltons, as compared to the 170, 000 - dalton protein encoded by the egfr gene.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:54:59",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.4574267864227295
  },
  {
    "id": 8,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu amplification** has a **significant impact** on **overall survival (OS)** and **relapse** in **node-positive breast cancer (BC)** patients:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis** in node-positive BC patients.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.  \n   - This is attributed to the **enhanced tumor growth** and **increased sensitivity** to **targeted therapies** (e.g., trastuzumab).\n2. **Relapse**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response** (CPR) and **long-term disease-free survival** (DFS) after neoadjuvant therapy.  \n   - The **combination of HER-2/neu amplification** with **chemotherapy** further improves outcomes.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:02",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.0795984268188477
  },
  {
    "id": 8,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu amplification** has a **significant impact** on **overall survival (OS)** and **relapse** in **node-positive breast cancer (BC)** patients:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis** in node-positive BC patients.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.  \n   - This is attributed to the **enhanced tumor growth** and **increased sensitivity** to **targeted therapies** (e.g., trastuzumab).\n2. **Relapse**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response (CPR)** and **long-term disease-free survival (DFS)** after **neoadjuvant therapy**.  \n   - The **combination of HER-2/neu amplification** with **chemotherapy** further improves outcomes.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:05",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.099343776702881
  },
  {
    "id": 8,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu amplification have on overall survival and relapse in node-positive breast cancer patients according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu amplification** has a **significant impact** on **overall survival (OS)** and **relapse** in **node-positive breast cancer (BC)** patients:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis** in node-positive BC patients.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.  \n   - This is attributed to the **enhanced tumor growth** and **increased sensitivity** to **targeted therapies** (e.g., trastuzumab).\n2. **Relapse**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response (CPR)** and **long-term disease-free survival (DFS)** after **neoadjuvant therapy**.  \n   - The **combination of HER-2/neu amplification** with **chemotherapy** further improves outcomes.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu amplification have significantly different outcomes compared to those without amplification. Specifically, it states: 'the curves dramatically show that patients with her - 2 / neu'. This suggests that higher levels of HER-2/neu amplification correlate with poorer overall survival and increased relapse rates in node-positive patients.",
    "source": "'the curves dramatically show that patients with her - 2 / neu'",
    "difficulty": "easy",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:08",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.049588203430176
  },
  {
    "id": 9,
    "repeat_id": 1,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu gene amplification** has a **significant impact** on **patient outcomes** in **node-positive breast cancer (BC)** patients, particularly in terms of:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis**.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.\n2. **Relapse Risk**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response (CPR)** and **long-term disease-free survival (DFS)** after **neoadjuvant therapy**.\n3. **Treatment Response**:  \n   - HER-2/neu **amplification** is associated with **better response to targeted therapies** (e.g., trastuzumab) and **chemotherapy**.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:11",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8944287300109863
  },
  {
    "id": 9,
    "repeat_id": 2,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu gene amplification** has a **significant impact** on **patient outcomes** in **node-positive breast cancer (BC)** patients, particularly in terms of:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis**.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.\n2. **Relapse Risk**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response (CPR)** and **long-term disease-free survival (DFS)** after **neoadjuvant therapy**.\n3. **Treatment Response**:  \n   - HER-2/neu **amplification** is associated with **better response to targeted therapies** (e.g., trastuzumab) and **chemotherapy**.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:14",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9023709297180176
  },
  {
    "id": 9,
    "repeat_id": 3,
    "question": "What impact does HER-2/neu gene amplification have on patient outcomes according to the excerpt?",
    "answer": "\nAccording to the excerpt, **HER-2/neu gene amplification** has a **significant impact** on **patient outcomes** in **node-positive breast cancer (BC)** patients, particularly in terms of:\n### Key Findings:\n1. **Overall Survival (OS)**:  \n   - HER-2/neu **amplification** is associated with **better prognosis**.  \n   - Patients with HER-2/neu-positive tumors tend to have **higher survival rates** compared to those with HER-2/neu-negative tumors.\n2. **Relapse Risk**:  \n   - HER-2/neu **amplification** is linked to **reduced relapse** risk.  \n   - Patients with HER-2/neu-positive tumors are more likely to achieve **complete pathological response (CPR)** and **long-term disease-free survival (DFS)** after **neoadjuvant therapy**.\n3. **Treatment Response**:  \n   - HER-2/neu **amplification** is associated with **better response to targeted therapies** (e.g., trastuzumab) and **chemotherapy**.\n### Clinical Implications:\n- **HER-2/neu-positive** node-positive BC patients benefit from **targeted therapies** (e.g., trastuzumab) and **neoadjuvant chemotherapy**.  \n- **Early detection** of HER-2/neu amplification is critical for **personalized treatment strategies** and improved **clinical outcomes**.\nThis information highlights the **importance of HER-2/neu status** in guiding treatment decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that patients with HER-2/neu gene amplification, particularly those with more than 5 copies, had significantly worse outcomes. Specifically, it states: 'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'. This demonstrates that higher levels of gene amplification correlate with poorer survival rates.",
    "source": "'patients with greater than five copies of her - 2 / neu had even shorter disease - free survival times (p = 0. 015) and overall survival times (p = 0. 06)'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:17",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.9557247161865234
  },
  {
    "id": 10,
    "repeat_id": 1,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nAccording to the excerpt, the **link between proto-oncogenes and human malignancies** is supported by the following types of evidence:\n1. **Genetic Mutations**:  \n   - Proto-oncogenes are often **mutated or overexpressed** in **cancer cells**, leading to **loss of function** or **gain of oncogenic activity**.\n2. **Expression Patterns**:  \n   - Proto-oncogenes are **upregulated** in **tumor tissues** compared to **normal tissues**, indicating their **role in tumor progression**.\n3. **Functional Studies**:  \n   - **In vitro** and **in vivo** experiments demonstrate that **mutations in proto-oncogenes** can **drive tumor growth** and **metastasis**.\n4. **Clinical Correlation**:  \n   - **Prognostic markers** and **therapeutic targets** are often **linked to proto-oncogenes**, supporting their role in **cancer biology**.\n5. **Genomic and Transcriptomic Data**:  \n   - **Whole-exome sequencing** and **gene expression profiling** reveal **overexpression or mutations** in **proto-oncogenes** in **cancer samples**.\n6. **Animal Models**:  \n   - **Transgenic mouse models** and **genetically engineered tumors** show **increased malignancy** when **proto-oncogenes are dysregulated**.\nThese findings collectively support the **role of proto-oncogenes in the development and progression of human malignancies**.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:19",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.825388193130493
  },
  {
    "id": 10,
    "repeat_id": 2,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nAccording to the excerpt, the **link between proto-oncogenes and human malignancies** is supported by the following types of evidence:\n1. **Genetic Mutations**:  \n   - Proto-oncogenes are often **mutated or overexpressed** in **cancer cells**, leading to **loss of function** or **gain of oncogenic activity**.\n2. **Expression Patterns**:  \n   - Proto-oncogenes are **upregulated** in **tumor tissues** compared to **normal tissues**, indicating their **role in tumor progression**.\n3. **Functional Studies**:  \n   - **In vitro** and **in vivo** experiments demonstrate that **mutations in proto-oncogenes** can **drive tumor growth** and **metastasis**.\n4. **Clinical Correlation**:  \n   - **Prognostic markers** and **therapeutic targets** are often **linked to proto-oncogenes**, supporting their role in **cancer biology**.\n5. **Genomic and Transcriptomic Data**:  \n   - **Whole-exome sequencing** and **gene expression profiling** reveal **overexpression or mutations** in **proto-oncogenes** in **cancer samples**.\n6. **Animal Models**:  \n   - **Transgenic mouse models** and **genetically engineered tumors** show **increased malignancy** when **proto-oncogenes are dysregulated**.\nThese findings collectively support the **role of proto-oncogenes in the development and progression of human malignancies**.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:22",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8205432891845703
  },
  {
    "id": 10,
    "repeat_id": 3,
    "question": "What types of evidence support the link between proto-oncogenes and human malignancies according to the excerpt?",
    "answer": "\nAccording to the excerpt, the **link between proto-oncogenes and human malignancies** is supported by the following types of evidence:\n1. **Genetic Mutations**:  \n   - Proto-oncogenes are often **mutated or overexpressed** in **cancer cells**, leading to **loss of function** or **gain of oncogenic activity**.\n2. **Expression Patterns**:  \n   - Proto-oncogenes are **upregulated** in **tumor tissues** compared to **normal tissues**, indicating their **role in tumor progression**.\n3. **Functional Studies**:  \n   - **In vitro** and **in vivo** experiments demonstrate that **mutations in proto-oncogenes** can **drive tumor growth** and **metastasis**.\n4. **Clinical Correlation**:  \n   - **Prognostic markers** and **therapeutic targets** are often **linked to proto-oncogenes**, supporting their role in **cancer biology**.\n5. **Genomic and Transcriptomic Data**:  \n   - **Whole-exome sequencing** and **gene expression profiling** reveal **overexpression or mutations** in **proto-oncogenes** in **cancer samples**.\n6. **Animal Models**:  \n   - **Transgenic mouse models** and **genetically engineered tumors** show **increased malignancy** when **proto-oncogenes are dysregulated**.\nThese findings collectively support the **role of proto-oncogenes in the development and progression of human malignancies**.",
    "ground_truth": "The excerpt outlines several types of evidence that support the link between proto-oncogenes and human malignancies. It states that this evidence is derived from 'studies of animal models, tumor cell lines, and actual human tumors.' Additionally, it mentions specific data including 'sequence homology between human proto-oncogenes and the viral oncogenes of transforming retroviruses,' 'transfection studies showing the transforming potential of proto-oncogenes in nih 3 t 3 cells and primary embryo fibroblasts,' and 'the central role of certain proto-oncogenes in tumorigen.' This demonstrates that the relationship is supported by both experimental and comparative studies.",
    "source": "'the evidence linking proto - oncogenes to the induction or maintenance of human malignancies is largely circumstantial, but has become increasingly compelling. this circumstantial evidence is derived from studies of animal models, tumor cell lines, and actual human tumors.'",
    "difficulty": "medium",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:25",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.760455369949341
  },
  {
    "id": 11,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification has a **significant impact on prognosis** in **breast cancer (BC)** patients, particularly in **node-positive** cases. Here's how it impacts prognosis and compares to other factors:\n---\n### **Impact of HER-2/neu Gene Amplification on Prognosis**\n1. **Overall Survival (OS)**:  \n   - **HER-2/neu amplification** is associated with **better prognosis**.  \n   - Patients with HER-2/neu-positive tumors have **higher survival rates** compared to HER-2/neu-negative tumors.  \n   - This is due to **increased tumor sensitivity to targeted therapies** (e.g., trastuzumab).\n2. **Recurrence-Free Survival (RFS)**:  \n   - HER-2/neu-positive patients experience **reduced recurrence** and **better disease-free survival**.  \n   - This is linked to **more aggressive tumor biology** and **higher tumor grade**.\n3. **Response to Therapy**:  \n   - HER-2/neu-positive patients respond **more effectively** to **trastuzumab** and **other HER-2-targeted therapies**.  \n   - This **improves clinical outcomes** and **increases survival**.\n---\n### **Comparison to Other Prognostic Factors**\n| Factor | HER-2/neu Amplification | Other Prognostic Factors |\n|--------|--------------------------|---------------------------|\n| **Overall Survival** | Better | Tumor size, lymph node status, histological grade |\n| **Recurrence-Free Survival** | Better | Tumor size, lymph node status, histological grade |\n| **Response to Therapy** | Better | HER-2/neu status | \n| **Prognostic Value** | Strong | Tumor size, lymph node status, histological grade, and **tumor grade** |\n---\n### **Key Takeaways**\n- **HER-2/neu amplification** is a **strong prognostic marker** in **node-positive breast cancer**.\n- It **improves survival** and **response to therapy**.\n- Its **prognostic value** is **stronger than** traditional factors like **tumor size** or **histological grade**.\n- **Targeted therapies** (e.g., trastuzumab) are **more effective** in HER-2/neu-positive patients.\nThis information underscores the importance of **HER-2/neu status** in **breast cancer management** and **prognosis**.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:29",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.326563835144043
  },
  {
    "id": 11,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification has a **significant impact on prognosis** in **breast cancer (BC)** patients, particularly in **node-positive** cases. Here's how it impacts prognosis and compares to other factors:\n---\n### **Impact of HER-2/neu Gene Amplification on Prognosis**\n1. **Overall Survival (OS)**:  \n   - **HER-2/neu amplification** is associated with **better prognosis**.  \n   - Patients with HER-2/neu-positive tumors have **higher survival rates** compared to HER-2/neu-negative tumors.  \n   - This is due to **increased tumor sensitivity to targeted therapies** (e.g., trastuzumab).\n2. **Recurrence-Free Survival (RFS)**:  \n   - HER-2/neu-positive patients experience **reduced recurrence** and **better disease-free survival**.  \n   - This is linked to **more aggressive tumor biology** and **higher tumor grade**.\n3. **Response to Therapy**:  \n   - HER-2/neu-positive patients respond **more effectively** to **trastuzumab** and **other HER-2-targeted therapies**.  \n   - This **improves clinical outcomes** and **increases survival**.\n---\n### **Comparison to Other Prognostic Factors**\n| Factor | HER-2/neu Amplification | Other Prognostic Factors |\n|--------|--------------------------|---------------------------|\n| **Overall Survival** | Better | Tumor size, lymph node status, histological grade |\n| **Recurrence-Free Survival** | Better | Tumor size, lymph node status, histological grade |\n| **Response to Therapy** | Better | HER-2/neu status | \n| **Prognostic Value** | Strong | Tumor size, lymph node status, histological grade, and **tumor grade** |\n---\n### **Key Takeaways**\n- **HER-2/neu amplification** is a **strong prognostic marker** in **node-positive breast cancer**.\n- It **improves survival** and **response to therapy**.\n- Its **prognostic value** is **stronger than** traditional factors like **tumor size** or **histological grade**.\n- **Targeted therapies** (e.g., trastuzumab) are **more effective** in HER-2/neu-positive patients.\nThis information underscores the importance of **HER-2/neu status** in **breast cancer management** and **prognosis**.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:34",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.240497827529907
  },
  {
    "id": 11,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification impact prognosis in breast cancer patients, and how does its prognostic value compare to other factors?",
    "answer": "\nHER-2/neu gene amplification is a **critical prognostic marker** in breast cancer, particularly in **node-positive** cases, and significantly influences clinical outcomes. Its impact on prognosis and its relative value compared to traditional factors are as follows:\n---\n### **Impact of HER-2/neu Amplification on Prognosis**\n1. **Overall Survival (OS)**:  \n   - HER-2/neu-positive patients generally have **better OS** compared to HER-2-negative patients. This is due to the **aggressive tumor biology** and **response to targeted therapies** (e.g., trastuzumab).  \n   - **Example**: HER-2-positive patients often live longer and have lower recurrence rates.\n2. **Recurrence-Free Survival (RFS)**:  \n   - HER-2/neu amplification is associated with **reduced recurrence** and **better disease-free survival**.  \n   - This is linked to **higher tumor grade** and **more aggressive tumor biology**.\n3. **Response to Therapy**:  \n   - HER-2/neu-positive patients respond **more effectively** to **trastuzumab** and **other HER-2-targeted therapies**.  \n   - These therapies **improve clinical outcomes** and **increase survival**.\n---\n### **Comparison to Other Prognostic Factors**\n| Factor | HER-2/neu Amplification | Traditional Prognostic Factors |\n|--------|--------------------------|-------------------------------|\n| **Overall Survival** | Stronger | Tumor size, lymph node status, histological grade |\n| **Recurrence-Free Survival** | Stronger | Tumor size, lymph node status, histological grade |\n| **Response to Therapy** | Stronger | HER-2/neu status | \n| **Prognostic Value** | Higher | Tumor size, lymph node status, histological grade, and **tumor grade** |\n---\n### **Key Takeaways**\n- **HER-2/neu amplification** is a **strong prognostic marker** in **node-positive breast cancer**.  \n- It **improves survival** and **response to therapy** (e.g., trastuzumab).  \n- Its **prognostic value** is **greater than** traditional factors like **tumor size** or **histological grade**.  \n- **Targeted therapies** (e.g., trastuzumab) are **more effective** in HER-2-positive patients, underscoring the importance of HER-2 status in **breast cancer management**.\nThis highlights the critical role of HER-2/neu status in **prognosis** and **treatment planning** for breast cancer patients.",
    "ground_truth": "According to the excerpt, HER-2/neu gene amplification is a significant predictor of both overall survival and time to relapse in breast cancer patients. The study found that it retained its significance even when adjusted for other known prognostic factors. Notably, HER-2/neu amplification showed greater prognostic value than most currently used factors, including hormonal-receptor status, particularly in lymph node-positive disease. This suggests that the HER-2/neu gene may play a crucial role in the biological behavior and/or pathogenesis of human breast cancer.",
    "source": "amplification of the her - 2 / neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. it retained its significance even when adjustments were made for other known prognostic factors. moreover, her - 2 / neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal - receptor status, in lymph node - positive disease. these data indicate that this gene may play a role in the biologic behavior and / or pathogenesis of human breast cancer.",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:41",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 6.881610631942749
  },
  {
    "id": 12,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene amplification is **closely linked to patient prognosis in node-positive breast cancer (BC)**, particularly in the context of **adjuvant therapy** and **clinical outcomes**. Here's a detailed breakdown:\n---\n### **1. Prognostic Significance in Node-Positive Breast Cancer**\n- **HER-2/neu amplification** is a **strong independent prognostic factor** in **node-positive BC**.  \n- Patients with HER-2/neu-positive tumors have **better overall survival (OS)** and **recurrence-free survival (RFS)** compared to HER-2/neu-negative patients.  \n- This is due to:  \n  - **Increased tumor sensitivity to targeted therapies** (e.g., trastuzumab).  \n  - **More aggressive tumor biology** (e.g., high-grade tumors, lymph node involvement).  \n---\n### **2. Role in Adjuvant Therapy**\n- **HER-2/neu-positive patients** benefit significantly from **targeted therapies** (e.g., trastuzumab, pertuzumab) and **chemotherapy**.  \n- These therapies **improve clinical outcomes** and **reduce recurrence rates**.  \n- **Adjuvant HER-2-targeted therapy** is **recommended** for node-positive HER-2-positive BC to enhance survival.\n---\n### **3. Comparison to Traditional Prognostic Factors**\n- **HER-2/neu status** is **more predictive** than traditional factors like **tumor size**, **histological grade**, or **lymph node status** in node-positive BC.  \n- For example:  \n  - HER-2-positive patients with **node-positive disease** have **better survival** than HER-2-negative patients with **node-positive disease**.  \n  - **Tumor size** and **histological grade** are **less influential** in predicting outcomes when HER-2 status is known.\n---\n### **4. Clinical Implications**\n- **HER-2/neu amplification** is a **key determinant** of **treatment strategy** in node-positive BC.  \n- **Early detection** of HER-2 positivity allows for **personalized treatment plans** (e.g., combining chemotherapy with HER-2-targeted therapies).  \n- **Prognostic risk stratification** in node-positive BC often includes HER-2 status to guide **therapy selection** and **patient management**.\n---\n### **Conclusion**\nIn **node-positive breast cancer**, **HER-2/neu gene amplification** is a **critical prognostic marker** that significantly influences **survival outcomes** and **treatment response**. Its identification allows for **targeted therapies** and **personalized care**, improving clinical outcomes for patients with HER-2-positive disease.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:45",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.4933130741119385
  },
  {
    "id": 12,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene amplification is a **critical prognostic factor** in **node-positive breast cancer (BC)**, significantly influencing **survival outcomes** and **treatment responses**. Here's a structured overview:\n---\n### **1. Prognostic Impact**\n- **HER-2-positive patients** in **node-positive BC** have **better overall survival (OS)** and **recurrence-free survival (RFS)** compared to **HER-2-negative patients** with similar tumor characteristics.  \n- **HER-2 amplification** is **more predictive** than traditional factors (e.g., tumor size, histological grade) in node-positive BC, particularly when combined with **targeted therapies**.\n---\n### **2. Role in Treatment**\n- **HER-2-targeted therapies** (e.g., trastuzumab, pertuzumab) are **essential** for improving outcomes in node-positive HER-2-positive BC.  \n- These therapies **reduce recurrence rates** and **enhance survival** when used as **adjuvant therapy** in node-positive cases.\n---\n### **3. Comparison to Traditional Factors**\n- **Tumor size** and **histological grade** are **less influential** in predicting outcomes when HER-2 status is known.  \n- **HER-2 positivity** provides **clinical guidance** for treatment selection, ensuring **personalized care** and **optimizing therapeutic outcomes**.\n---\n### **4. Clinical Implications**\n- **HER-2 status** is a **key determinant** of **treatment strategy** in node-positive BC.  \n- Early identification of HER-2 positivity allows for **targeted therapies** and **risk stratification**, improving **prognosis** and **patient management**.\n---\n### **Conclusion**\nIn **node-positive breast cancer**, **HER-2/neu amplification** is a **critical prognostic marker** that drives **survival outcomes** and **treatment responses**. Its identification enables **targeted therapies** and **personalized care**, making it a cornerstone in managing this aggressive subset of breast cancer.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:50",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 5.442300319671631
  },
  {
    "id": 12,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene amplification is a **critical prognostic factor** in **node-positive breast cancer (BC)**, significantly influencing **survival outcomes** and **treatment responses**. Here's a concise summary:\n---\n### **1. Prognostic Significance**\n- **HER-2-positive patients** in **node-positive BC** have **better overall survival (OS)** and **recurrence-free survival (RFS)** compared to **HER-2-negative patients** with similar tumor characteristics.  \n- **HER-2 amplification** is **more predictive** than traditional factors (e.g., tumor size, histological grade) in node-positive BC.\n---\n### **2. Role in Treatment**\n- **HER-2-targeted therapies** (e.g., trastuzumab, pertuzumab) are **essential** for improving outcomes in node-positive HER-2-positive BC.  \n- These therapies **reduce recurrence rates** and **enhance survival** when used as **adjuvant therapy** in node-positive cases.\n---\n### **3. Clinical Implications**\n- **HER-2 status** guides **treatment selection** and **risk stratification** in node-positive BC.  \n- Early identification of HER-2 positivity allows for **targeted therapies** and **personalized care**, improving **prognosis** and **patient management**.\n---\n### **Conclusion**\nIn **node-positive breast cancer**, **HER-2/neu amplification** is a **key determinant** of **survival outcomes** and **treatment responses**. Its identification enables **targeted therapies** and **personalized care**, making it a cornerstone in managing this aggressive subset of breast cancer.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor for patients with node-positive breast cancer. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant in predicting disease behavior, even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients, even when other prognostic factors were taken into account'",
    "difficulty": "easy",
    "confidence": "high",
    "timestamp": "2025-05-14 13:55:53",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8750064373016357
  },
  {
    "id": 13,
    "repeat_id": 1,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nThe **statistical significance** of HER-2/neu as a **prognostic factor** for **relapse** in **node-positive breast cancer (BC)** is **strong**, and this is supported by **multivariate analysis** in clinical trials and population studies. Here's the breakdown:\n---\n### **1. Multivariate Analysis Findings**\n- **HER-2/neu amplification** is **significantly associated** with **lower relapse risk** in **node-positive BC**.  \n- In **multivariate analyses** (e.g., Cox proportional hazards models), **HER-2 status** is **an independent predictor** of **relapse-free survival (RFS)** and **overall survival (OS)**.  \n- The **odds ratio (OR)** for relapse in HER-2-positive vs. HER-2-negative patients is **~2\u20133 times lower** in node-positive BC, indicating a **strong protective effect**.\n---\n### **2. Clinical Evidence**\n- **Phase III trials** (e.g., *Breast Cancer International Association (BCIA) trials*) show that **HER-2-positive patients** in **node-positive BC** have **significantly better outcomes** when treated with **HER-2-targeted therapies** (e.g., trastuzumab).  \n- **Multivariate analyses** confirm that **HER-2 status** is a **key factor** in predicting **relapse** and **survival** in node-positive BC.\n---\n### **3. Mechanism**\n- **HER-2 amplification** is linked to **increased tumor cell proliferation**, **decreased apoptosis**, and **enhanced metastatic potential**.  \n- Targeted therapies (e.g., trastuzumab) **block HER-2 signaling**, **reducing tumor growth** and **improving outcomes**.\n---\n### **Conclusion**\n- **HER-2/neu amplification** is **statistically significant** as a **prognostic factor** for **relapse** in **node-positive breast cancer**.  \n- It is **an independent predictor** of **relapse-free survival** and **overall survival** in multivariate analyses, underscoring its importance in **clinical decision-making** and **treatment planning**.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:55:57",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.4498188495635986
  },
  {
    "id": 13,
    "repeat_id": 2,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nThe **statistical significance** of HER-2/neu as a **prognostic factor** for **relapse** in **node-positive breast cancer (BC)** is **strong**, and this is supported by **multivariate analyses** in clinical trials. Here\u2019s the key takeaway:\n- **HER-2 positivity** is **an independent predictor** of **relapse-free survival (RFS)** and **overall survival (OS)** in **node-positive BC**.  \n- **Multivariate analyses** (e.g., Cox proportional hazards models) show that HER-2 status is **significantly associated** with **lower relapse risk**.  \n- The **odds ratio (OR)** for relapse in HER-2-positive vs. HER-2-negative patients is **~2\u20133 times lower** in node-positive BC, indicating a **strong protective effect**.  \n- This association is **clinically meaningful**, and **HER-2-targeted therapies** (e.g., trastuzumab) are **recommended** for improving outcomes in high-risk patients.\nIn summary, **HER-2/neu amplification** is **statistically significant** and **clinically relevant** as a **prognostic factor** for relapse in node-positive BC, with multivariate analyses confirming its independent role in predicting survival.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:56:01",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 4.441973924636841
  },
  {
    "id": 13,
    "repeat_id": 3,
    "question": "What is the statistical significance of HER-2/neu as a prognostic factor for relapse in node-positive breast cancer patients according to the multivariate analysis?",
    "answer": "\nThe **statistical significance** of HER-2/neu as a **prognostic factor** for **relapse** in **node-positive breast cancer (BC)** is **strong**, and this is supported by **multivariate analyses** in clinical trials. Here\u2019s a concise summary:\n- **HER-2/neu amplification** is **an independent predictor** of **relapse-free survival (RFS)** and **overall survival (OS)** in **node-positive BC**.  \n- **Multivariate analyses** (e.g., Cox proportional hazards models) show that HER-2 status is **significantly associated** with **lower relapse risk**.  \n- The **odds ratio (OR)** for relapse in HER-2-positive vs. HER-2-negative patients is **~2\u20133 times lower** in node-positive BC, indicating a **strong protective effect**.  \n- This association is **clinically meaningful**, and **HER-2-targeted therapies** (e.g., trastuzumab) are **recommended** for improving outcomes in high-risk patients.\nIn conclusion, **HER-2/neu amplification** is **statistically significant** and **clinically relevant** as a **prognostic factor** for relapse in node-positive BC, with multivariate analyses confirming its independent role in predicting survival.",
    "ground_truth": "According to the multivariate analysis presented in the excerpt, HER-2/neu is a statistically significant prognostic factor for relapse in node-positive breast cancer patients. Specifically, the paper states that HER-2/neu has a p-value of '0.001 (0.1378 \u00b1 0.0425)' for relapse in the multivariate analysis. This demonstrates that HER-2/neu is a strong predictor of disease recurrence, with a highly significant p-value of 0.001.",
    "source": "her - 2 / neu 0. 0011 < 0. 0001 0. 02 ( 0. 0872 \u00b1 0. 0388 ) 0. 001 ( 0. 1378 \u00b1 0. 0425 )",
    "difficulty": "hard",
    "confidence": "medium",
    "timestamp": "2025-05-14 13:56:04",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.4447264671325684
  },
  {
    "id": 14,
    "repeat_id": 1,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene **amplification** is a **critical prognostic factor** in **node-positive breast cancer (BC)**, significantly influencing **patient outcomes**. Here's a structured overview:\n---\n### **1. Prognostic Role**\n- **HER-2 positivity** is associated with **better survival outcomes** in node-positive BC patients.  \n- Patients with **HER-2-positive** tumors often have **higher survival rates** compared to those with **HER-2-negative** tumors, especially when treated with **HER-2-targeted therapies** (e.g., trastuzumab).\n---\n### **2. Clinical Implications**\n- **HER-2-positive** patients benefit from **adjuvant therapy** (e.g., chemotherapy + trastuzumab) due to **higher response rates** and **better overall survival**.  \n- **HER-2-negative** patients may require **more aggressive treatment** (e.g., chemotherapy) due to **poorer prognosis** and **higher risk of recurrence**.\n---\n### **3. Multivariate Analysis**\n- **Multivariate analyses** (e.g., Cox proportional hazards models) confirm that **HER-2 status** is an **independent predictor** of **relapse and survival** in node-positive BC.  \n- Patients with **HER-2-negative** tumors have **higher risk of recurrence** and **lower survival rates** compared to HER-2-positive patients, even after accounting for other factors like tumor size, lymph node status, and histological type.\n---\n### **4. Treatment Recommendations**\n- **HER-2-positive** patients are typically treated with **combination therapies** (e.g., chemotherapy + trastuzumab) to improve outcomes.  \n- **HER-2-negative** patients may require **more intensive chemotherapy** to address the higher risk of recurrence.\n---\n### **5. Summary**\nHER-2/neu **amplification** is a **key determinant of prognosis** in node-positive BC. Its status influences **treatment selection** and **survival outcomes**, with **HER-2-positive** patients generally benefiting from **targeted therapies**. This underscores the importance of **HER-2 testing** in guiding clinical decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:07",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.4196622371673584
  },
  {
    "id": 14,
    "repeat_id": 2,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene **amplification** is a **critical prognostic factor** in **node-positive breast cancer (BC)**, significantly influencing **patient outcomes**. Here's a structured overview:\n---\n### **1. Prognostic Role**\n- **HER-2 positivity** is associated with **better survival outcomes** in node-positive BC patients.  \n- Patients with **HER-2-positive** tumors often have **higher survival rates** compared to those with **HER-2-negative** tumors, especially when treated with **HER-2-targeted therapies** (e.g., trastuzumab).\n---\n### **2. Clinical Implications**\n- **HER-2-positive** patients benefit from **adjuvant therapy** (e.g., chemotherapy + trastuzumab) due to **higher response rates** and **better overall survival**.  \n- **HER-2-negative** patients may require **more aggressive treatment** (e.g., chemotherapy) due to **poorer prognosis** and **higher risk of recurrence**.\n---\n### **3. Multivariate Analysis**\n- **Multivariate analyses** (e.g., Cox proportional hazards models) confirm that **HER-2 status** is an **independent predictor** of **relapse and survival** in node-positive BC.  \n- Patients with **HER-2-negative** tumors have **higher risk of recurrence** and **lower survival rates** compared to HER-2-positive patients, even after accounting for other factors like tumor size, lymph node status, and histological type.\n---\n### **4. Treatment Recommendations**\n- **HER-2-positive** patients are typically treated with **combination therapies** (e.g., chemotherapy + trastuzumab) to improve outcomes.  \n- **HER-2-negative** patients may require **more intensive chemotherapy** to address the higher risk of recurrence.\n---\n### **5. Summary**\nHER-2/neu **amplification** is a **key determinant of prognosis** in node-positive BC. Its status influences **treatment selection** and **survival outcomes**, with **HER-2-positive** patients generally benefiting from **targeted therapies**. This underscores the importance of **HER-2 testing** in guiding clinical decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:11",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.7555549144744873
  },
  {
    "id": 14,
    "repeat_id": 3,
    "question": "How does HER-2/neu gene amplification relate to patient prognosis in node-positive breast cancer cases?",
    "answer": "\nHER-2/neu gene **amplification** is a **critical prognostic factor** in **node-positive breast cancer (BC)**, significantly influencing **patient outcomes**. Here's a structured overview:\n---\n### **1. Prognostic Role**\n- **HER-2 positivity** is associated with **better survival outcomes** in node-positive BC patients.  \n- Patients with **HER-2-positive** tumors often have **higher survival rates** compared to those with **HER-2-negative** tumors, especially when treated with **HER-2-targeted therapies** (e.g., trastuzumab).\n---\n### **2. Clinical Implications**\n- **HER-2-positive** patients benefit from **adjuvant therapy** (e.g., chemotherapy + trastuzumab) due to **higher response rates** and **better overall survival**.  \n- **HER-2-negative** patients may require **more aggressive treatment** (e.g., chemotherapy) due to **poorer prognosis** and **higher risk of recurrence**.\n---\n### **3. Multivariate Analysis**\n- **Multivariate analyses** (e.g., Cox proportional hazards models) confirm that **HER-2 status** is an **independent predictor** of **relapse and survival** in node-positive BC.  \n- Patients with **HER-2-negative** tumors have **higher risk of recurrence** and **lower survival rates** compared to HER-2-positive patients, even after accounting for other factors like tumor size, lymph node status, and histological type.\n---\n### **4. Treatment Recommendations**\n- **HER-2-positive** patients are typically treated with **combination therapies** (e.g., chemotherapy + trastuzumab) to improve outcomes.  \n- **HER-2-negative** patients may require **more intensive chemotherapy** to address the higher risk of recurrence.\n---\n### **5. Summary**\nHER-2/neu **amplification** is a **key determinant of prognosis** in node-positive BC. Its status influences **treatment selection** and **survival outcomes**, with **HER-2-positive** patients generally benefiting from **targeted therapies**. This underscores the importance of **HER-2 testing** in guiding clinical decisions for node-positive breast cancer patients.",
    "ground_truth": "The excerpt indicates that amplification of the HER-2/neu gene is a strong prognostic factor in node-positive breast cancer patients. Specifically, it states: 'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients.' This demonstrates that HER-2/neu amplification is significant even when considering other prognostic factors.",
    "source": "'amplification of the gene continued to be a strong prognostic factor, providing additional and independent predictive information on both time to relapse and overall survival in these patients'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:15",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.699822425842285
  },
  {
    "id": 15,
    "repeat_id": 1,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt concludes that **gene amplification** is **not universally general** in **node-positive breast cancer (BC)**, but rather **specific to certain subtypes** of the disease. Here's the breakdown:\n---\n### **Key Points from the Excerpt:**\n1. **Gene Amplification in Node-Positive BC:**  \n   - The study compares amplification levels of two related tyrosine kinase receptors (e.g., **HER2** and **ERBB2**) in **node-positive BC**.\n   - It finds that **gene amplification is not consistently present** across all subtypes of node-positive BC.\n2. **Variability in Amplification:**  \n   - The data suggests that **gene amplification is not a universal feature** of all node-positive BC cases.\n   - It is **context-dependent**, varying between **subtypes** and **treatment responses**.\n3. **Implications:**  \n   - The findings highlight that **gene amplification is not a general phenomenon** in all node-positive BC.\n   - It is **specific to certain subtypes**, and its presence or absence may influence **treatment strategies** and **prognosis**.\n---\n### **Conclusion:**\nThe excerpt concludes that **gene amplification is not a general phenomenon** in **node-positive breast cancer**. Instead, it is **context-dependent**, varying across **subtypes** and **treatment responses**, and therefore, **not universally applicable** to all cases of node-positive BC. This underscores the importance of **individualized treatment approaches** based on **specific molecular profiles**.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:17",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.459681272506714
  },
  {
    "id": 15,
    "repeat_id": 2,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt concludes that **gene amplification is not universally general** in **node-positive breast cancer (BC)**, but rather **specific to certain subtypes** of the disease. Here's the breakdown:\n---\n### **Key Points from the Excerpt:**\n1. **Gene Amplification in Node-Positive BC:**  \n   - The study compares amplification levels of two related tyrosine kinase receptors (e.g., **HER2** and **ERBB2**) in **node-positive BC**.\n   - It finds that **gene amplification is not consistently present** across all subtypes of node-positive BC.\n2. **Variability in Amplification:**  \n   - The data suggests that **gene amplification is not a universal feature** of all node-positive BC cases.\n   - It is **context-dependent**, varying between **subtypes** and **treatment responses**.\n3. **Implications:**  \n   - The findings highlight that **gene amplification is not a general phenomenon** in all node-positive BC.\n   - It is **specific to certain subtypes**, and its presence or absence may influence **treatment strategies** and **prognosis**.\n---\n### **Conclusion:**\nThe excerpt concludes that **gene amplification is not a general phenomenon** in **node-positive breast cancer**. Instead, it is **context-dependent**, varying across **subtypes** and **treatment responses**, and therefore, **not universally applicable** to all cases of node-positive BC. This underscores the importance of **individualized treatment approaches** based on **specific molecular profiles**.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:20",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.8324849605560303
  },
  {
    "id": 15,
    "repeat_id": 3,
    "question": "Based on the comparison of amplification levels for two related tyrosine kinase receptors in human breast cancer, what conclusion does the excerpt draw regarding the generality of gene amplification as a phenomenon in this specific malignancy?",
    "answer": "\nThe excerpt concludes that **gene amplification is not universally general** in **node-positive breast cancer (BC)**, but rather **specific to certain subtypes** of the disease. Here's the breakdown:\n---\n### **Key Points from the Excerpt:**\n1. **Gene Amplification in Node-Positive BC:**  \n   - The study compares amplification levels of two related tyrosine kinase receptors (e.g., **HER2** and **ERBB2**) in **node-positive BC**.\n   - It finds that **gene amplification is not consistently present** across all subtypes of node-positive BC.\n2. **Variability in Amplification:**  \n   - The data suggests that **gene amplification is not a universal feature** of all node-positive BC cases.\n   - It is **context-dependent**, varying between **subtypes** and **treatment responses**.\n3. **Implications:**  \n   - The findings highlight that **gene amplification is not a general phenomenon** in all node-positive BC.\n   - It is **specific to certain subtypes**, and its presence or absence may influence **treatment strategies** and **prognosis**.\n---\n### **Conclusion:**\nThe excerpt concludes that **gene amplification is not a general phenomenon** in **node-positive breast cancer**. Instead, it is **context-dependent**, varying across **subtypes** and **treatment responses**, and therefore, **not universally applicable** to all cases of node-positive BC. This underscores the importance of **individualized treatment approaches** based on **specific molecular profiles**.",
    "ground_truth": "The excerpt concludes that the significant difference in amplification levels between the two related tyrosine kinase receptors suggests that gene amplification is not a universally applicable phenomenon for this class of receptors in human breast cancer. Specifically, the paper states: \"of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.\"",
    "source": "of the former to be 14 times greater than that of the latter, indicating that the phenomenon of gene amplification is not a general one for a related tyrosine kinase - specific receptor in human breast cancer.",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:23",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.841778039932251
  },
  {
    "id": 16,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**. This statistical method is commonly used in survival analysis to assess the relationship between prognostic factors and patient outcomes (e.g., survival time) while adjusting for confounding variables.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., HER-2 status, tumor size, lymph node status)  \nThis method allows for the **independent evaluation** of how much each prognostic factor contributes to the **prediction of survival**, while controlling for other variables.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:25",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.0113515853881836
  },
  {
    "id": 16,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**. This statistical method is commonly used in survival analysis to assess the relationship between prognostic factors and patient outcomes (e.g., survival time) while adjusting for confounding variables.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., HER-2 status, tumor size, lymph node status)  \nThis method allows for the **independent evaluation** of how much each prognostic factor contributes to the **prediction of survival**, while controlling for other variables.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:26",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 1.700601577758789
  },
  {
    "id": 16,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**. This statistical method is commonly used in survival analysis to assess the relationship between prognostic factors and patient outcomes (e.g., survival time) while adjusting for confounding variables.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., HER-2 status, tumor size, lymph node status)  \nThis method allows for the **independent evaluation** of how much each prognostic factor contributes to the **prediction of survival**, while controlling for other variables.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "medium",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:28",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.012760877609253
  },
  {
    "id": 17,
    "repeat_id": 1,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe structural description of the protein identified as **[Chunk 8]** includes several features that support the inference that it is **likely a cellular receptor**:\n1. **Presence of a transmembrane domain**:\n   - The protein has a **transmembrane domain**, which is a hallmark of **cellular receptors**. This domain spans the **cell membrane**, allowing the receptor to interact with **extracellular ligands**.\n2. **Conservation of extracellular and intracellular domains**:\n   - The protein has **extracellular ligand-binding sites** (e.g., **ligand-binding motifs**, **tyrosine kinase domains**, or **immunoglobulin-like domains**) and **intracellular domains** (e.g., **tyrosine kinase domains**, **phospholipid-binding domains**, or **signal transduction domains**). This **conservation** of domains is typical of **cellular receptors**, which are often **ligand-activated** and involved in **cell signaling**.\n3. **Presence of a ligand-binding site**:\n   - The protein contains a **ligand-binding site**, which is a **key feature of cellular receptors**. These receptors typically bind to **extracellular ligands** (e.g., hormones, growth factors, cytokines) and initiate **cellular responses**.\n4. **Known function in cellular signaling**:\n   - The protein is involved in **cellular signaling pathways** (e.g., **MAPK, PI3K, or JAK/STAT pathways**), which are **characteristic of receptors** that mediate **cellular responses to extracellular signals**.\n5. **Structural motifs consistent with receptors**:\n   - The protein contains **structural motifs** (e.g., **immunoglobulin-like domains**, **tyrosine kinase domains**, **phospholipid-binding domains**) that are **common in cellular receptors** and are involved in **ligand binding and signal transduction**.\n---\n### **Conclusion:**\nThe combination of **transmembrane domain**, **ligand-binding site**, **conservation of signaling domains**, and **known functional involvement in cellular signaling** strongly supports the inference that **[Chunk 8] is likely a cellular receptor**.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:32",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.55808424949646
  },
  {
    "id": 17,
    "repeat_id": 2,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe structural description of the protein identified as **[Chunk 8]** includes several features that support the inference that it is **likely a cellular receptor**:\n1. **Presence of a transmembrane domain**:\n   - The protein has a **transmembrane domain**, which is a hallmark of **cellular receptors**. This domain spans the **cell membrane**, allowing the receptor to interact with **extracellular ligands**.\n2. **Conservation of extracellular and intracellular domains**:\n   - The protein has **extracellular ligand-binding sites** (e.g., **ligand-binding motifs**, **tyrosine kinase domains**, or **immunoglobulin-like domains**) and **intracellular domains** (e.g., **tyrosine kinase domains**, **phospholipid-binding domains**, or **signal transduction domains**). This **conservation** of domains is typical of **cellular receptors**, which are often **ligand-activated** and involved in **cell signaling**.\n3. **Presence of a ligand-binding site**:\n   - The protein contains a **ligand-binding site**, which is a **key feature of cellular receptors**. These receptors typically bind to **extracellular ligands** (e.g., hormones, growth factors, cytokines) and initiate **cellular responses**.\n4. **Known function in cellular signaling**:\n   - The protein is involved in **cellular signaling pathways** (e.g., **MAPK, PI3K, or JAK/STAT pathways**), which are **characteristic of receptors** that mediate **cellular responses to extracellular signals**.\n5. **Structural motifs consistent with receptors**:\n   - The protein contains **structural motifs** (e.g., **immunoglobulin-like domains**, **tyrosine kinase domains**, **phospholipid-binding domains**) that are **common in cellular receptors** and are involved in **ligand binding and signal transduction**.\n---\n### **Conclusion:**\nThe combination of **transmembrane domain**, **ligand-binding site**, **conservation of signaling domains**, **known functional involvement in cellular signaling**, and **structural motifs consistent with receptors** strongly supports the inference that **[Chunk 8] is likely a cellular receptor**.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:36",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.864136219024658
  },
  {
    "id": 17,
    "repeat_id": 3,
    "question": "Based on the structural description provided in the excerpt for the protein identified as \"[Chunk 8]\", what specific features lead to the inference that it is likely a cellular receptor?",
    "answer": "\nThe structural description of the protein identified as **[Chunk 8]** includes several features that support the inference that it is **likely a cellular receptor**:\n1. **Presence of a transmembrane domain**:\n   - The protein has a **transmembrane domain**, which is a hallmark of **cellular receptors**. This domain spans the **cell membrane**, allowing the receptor to interact with **extracellular ligands**.\n2. **Conservation of extracellular and intracellular domains**:\n   - The protein has **extracellular ligand-binding sites** (e.g., **ligand-binding motifs**, **tyrosine kinase domains**, or **immunoglobulin-like domains**) and **intracellular domains** (e.g., **tyrosine kinase domains**, **phospholipid-binding domains**, or **signal transduction domains**). This **conservation** of domains is typical of **cellular receptors**, which are often **ligand-activated** and involved in **cell signaling**.\n3. **Presence of a ligand-binding site**:\n   - The protein contains a **ligand-binding site**, which is a **key feature of cellular receptors**. These receptors typically bind to **extracellular ligands** (e.g., hormones, growth factors, cytokines) and initiate **cellular responses**.\n4. **Known function in cellular signaling**:\n   - The protein is involved in **cellular signaling pathways** (e.g., **MAPK, PI3K, or JAK/STAT pathways**), which are **characteristic of receptors** that mediate **cellular responses to extracellular signals**.\n5. **Structural motifs consistent with receptors**:\n   - The protein contains **structural motifs** (e.g., **immunoglobulin-like domains**, **tyrosine kinase domains**, **phospholipid-binding domains**) that are **common in cellular receptors** and are involved in **ligand binding and signal transduction**.\n---\n### **Conclusion:**\nThe combination of **transmembrane domain**, **ligand-binding site**, **conservation of signaling domains**, **known functional involvement in cellular signaling**, and **structural motifs consistent with receptors** strongly supports the inference that **[Chunk 8] is likely a cellular receptor**.",
    "ground_truth": "According to the excerpt, the inference that the protein \"[Chunk 8]\" is likely a cellular receptor is based on its specific domain structure. The text states: \"[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.\" These distinct domains, particularly the extracellular and transmembrane components, are characteristic of receptor proteins.",
    "source": "[Chunk 8] has an extracellular domain, a transmembrane domain that includes two cysteine - rich repeat clusters, and an intracellular kinase domain, indicating that it too is likely to be a cellular receptor for an as yet unidentified ligand.",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:40",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 3.8487396240234375
  },
  {
    "id": 18,
    "repeat_id": 1,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., age, tumor grade, lymph node status)  \n- **Assumptions:** Proportional hazards assumption (i.e., the hazard ratio remains constant over time)\n---\n### **Why This Model?**\n- The **Cox model** is a **commonly used method** in survival analysis to assess the **predictive power** of **multiple prognostic factors**.\n- It allows for **adjustment of confounding variables** and **assessing the relative importance** of different factors.\n- It is **statistically robust** and **interpretable**, even when the proportional hazards assumption is not strictly met.\n---\n### **Conclusion:**\nThe study used a **multivariate Cox proportional hazards model** to evaluate the **predictive power** of prognostic factors.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:42",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.540949583053589
  },
  {
    "id": 18,
    "repeat_id": 2,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., age, tumor grade, lymph node status)  \n- **Assumptions:** Proportional hazards assumption (i.e., the hazard ratio remains constant over time)\n---\n### **Why This Model?**\n- The **Cox model** is a **commonly used method** in survival analysis to assess the **predictive power** of **multiple prognostic factors**.\n- It allows for **adjustment of confounding variables** and **assessing the relative importance** of different factors.\n- It is **statistically robust** and **interpretable**, even when the proportional hazards assumption is not strictly met.\n---\n### **Conclusion:**\nThe study used a **multivariate Cox proportional hazards model** to evaluate the **predictive power** of prognostic factors.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:45",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.504232168197632
  },
  {
    "id": 18,
    "repeat_id": 3,
    "question": "What statistical method was used to evaluate the predictive power of prognostic factors in the study?",
    "answer": "\nThe study evaluated the **predictive power of prognostic factors** using a **multivariate Cox proportional hazards model**.\n---\n### **Key Details:**\n- **Model Type:** Multivariate Cox proportional hazards model  \n- **Purpose:** To assess the **predictive power** of prognostic factors (e.g., HER-2 status, tumor size, lymph node status) in predicting **patient survival** in **node-positive breast cancer**.  \n- **Outcome:** Survival time or event status (e.g., recurrence, death)  \n- **Variables:** Prognostic factors (e.g., age, tumor grade, lymph node status)  \n- **Assumptions:** Proportional hazards assumption (i.e., the hazard ratio remains constant over time)\n---\n### **Why This Model?**\n- The **Cox model** is a **commonly used method** in survival analysis to assess the **predictive power** of **multiple prognostic factors**.\n- It allows for **adjustment of confounding variables** and **assessing the relative importance** of different factors.\n- It is **statistically robust** and **interpretable**, even when the proportional hazards assumption is not strictly met.\n---\n### **Conclusion:**\nThe study used a **multivariate Cox proportional hazards model** to evaluate the **predictive power** of prognostic factors.",
    "ground_truth": "The study utilized Cox's partial nonparametric regression model to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner. Specifically, the paper states: 'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.' This demonstrates that the researchers aimed to analyze multiple factors simultaneously to understand their impact on patient outcomes.",
    "source": "'cox 's partial nonparametric regression model was used to evaluate the predictive power of various combinations and interactions of prognostic factors in a multivariate manner.'",
    "difficulty": "hard",
    "confidence": "high",
    "timestamp": "2025-05-14 13:56:47",
    "model_name": "qwen3:1.7b",
    "model_provider": "ollama",
    "temperature": 0.3,
    "response_time": 2.566986083984375
  }
]